Newsletter

FDA Accepts Application for Investigational New Drug From Sangamo and Bioverativ

On October 2, Sangamo Biosciences (SGMO) and Bioverativ Inc. (BIVV) announced that the FDA accepted their application for an investigational new drug (IND). The drug, ST-400, is a gene-edited cell therapy candidate for people with transfusion-dependent-beta-thalassemia. There are about 100,000 patients being treated worldwide for this disease, which requires frequent blood transfusions.   Sonal sent […]

Read more...

AECOM Reveals Stock Repurchase Program

After the close of the markets on September 21, AECOM (ACM) unveiled a new capital allocation policy and stock repurchase program. AECOM is a global infrastructure firm that plans to spend all available free cash flow to pay down debt until reaching a target level sometime in 2018. This plan includes a stock repurchase program […]

Read more...

QUAD Lands $450 Million Contract

On September 20, Quad Graphics reported that it landed a $450 million printing contract. The Minnesota-based company will print all catalogs for the online retailer and fellow Minnesotans, Bluestem Brands, Inc.   The news triggered a level 3 Sonal alert at 4:05 pm. The next trade occurred at 4:13 pm in after-hours trading for $20.1645. […]

Read more...

LCI Receives FDA Approval for New Drug

Lannett Company (LCI) announced on September 27 that is had received FDA approval for a new drug. The Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg are the therapeutic equivalent to the drug Percocet. U.S. sales of Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg totaled around […]

Read more...